# 2026-09242: FDA Grants Priority Review Voucher for Rare Pediatric Drug

2026-09242, Issuance of Priority Review Voucher; Rare Pediatric Disease Product; AVLAYAH (tividenofusp alfa-eknm), is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-05-11, effective 2026-05-11; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-09242
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-09242
- Title: Issuance of Priority Review Voucher; Rare Pediatric Disease Product; AVLAYAH (tividenofusp alfa-eknm)
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 25582
- Published: 2026-05-11
- Effective: 2026-05-11
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Grants Priority Review Voucher for Rare Pediatric Drug

## Summary

The FDA just gave Denali Therapeutics a special priority review voucher for their rare pediatric disease drug AVLAYAH, approved in March 2026. This voucher speeds up the review of future medicines, helping kids with rare diseases get treatments faster. It’s a big win for patients, the company, and anyone watching rare disease drug development!

## Abstract

The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that AVLAYAH (tividenofusp alfa-eknm), approved March 24, 2026, manufactured by Denali Therapeutics Inc., meets the criteria for a priority review voucher.

## Effects PRIA read

- Priority Review Voucher Awarded to Sponsor: benefit, medium. The FDA issued a priority review voucher to Denali Therapeutics Inc. for AVLAYAH (tividenofusp alfa-eknm); AVLAYAH was approved March 24, 2026. The voucher was awarded under section 529 of the Federal Food, Drug, and Cosmetic Act.
- New FDA Approval for Hunter Syndrome Pediatrics: benefit, high. AVLAYAH (tividenofusp alfa-eknm) was approved March 24, 2026 for the treatment of neurologic manifestations of Hunter syndrome (Mucopolysaccharidosis type II). The approval applies when treatment is started in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-09242 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/11/2026-09242/issuance-of-priority-review-voucher-rare-pediatric-disease-product-avlayah-tividenofusp-alfa-eknm)
- [2026-09242 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-11/pdf/2026-09242.pdf)

## Related
- [Previous: 2026-09241, Notice of Receipt of Amended Complaint; Solicitation of Comments Relating to th…](https://policyrisk.com/federal-register/2026-09241)
- [Next: 2026-09243, Certain Photodynamic Therapy Systems, Components Thereof, and Pharmaceutical Pr…](https://policyrisk.com/federal-register/2026-09243)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-09242 (as of 2026-06-08).
